Lineage Cell Therapeutics, Inc. (LCTX) — Insider Activity & Signal

Healthcare · Biotechnology · Market cap $322M · $1.29 · 52-week range $0.93–$2.09

Recent insider buying

Open-market purchases reported to the SEC (last six months). Option grants and tax-withholding sales are excluded.

Date	Insider	Role	Shares	Price	Value	Source
2026-03-12	Culley Brian M	director, officer: President and CEO	15,000	$1.62	$24,375	SEC Form 4

Financial health

Altman Z-Score -3.16 · Piotroski F-Score 3/9 · Cash $56M · Debt $2M

ClearOcean signal read

ClearOcean's model currently scores LCTX as a watchlist-level signal (5/10), based on the insider, fundamental and risk data above. This is a factual model output, not advice.

Sources & further reading

Primary filings: SEC EDGAR — LCTX Form 4
How ClearOcean reads insider activity

Last updated July 10, 2026.

ClearOcean is a software research tool, not an investment adviser or broker-dealer. This page aggregates public data (incl. SEC filings) for informational purposes only — it is not investment advice, nor a recommendation, offer or solicitation to buy or sell any security. Past activity does not predict future results. You are solely responsible for your decisions; investing can lose value, up to total loss of capital.